Rubicon Research Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹476Cr
- +52.1% YoY
- +15.5% QoQ
- Net profit
- ₹73Cr
- +92.1% YoY
- +35.2% QoQ
- Margin
- 23%
- +1 pp YoY
- 0 pp QoQ
Guidance rank: #69 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products.
From Rubicon Research's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products.
- Specialty portfolio contribution to gross profit has increased from around 27% to about 31-32%, and is expected to continue growing.
- R&D productivity has improved (from 3.3x to 5.7x revenue multiple over R&D spend), supporting sustainable incremental revenue growth.
- The ramp-up of the Pithampur manufacturing facility in CY 2026 - early CY 2027 is expected to aid capacity, supporting revenue growth.
2 more points from Rubicon Research's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rubicon Research said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company acquired the Pithampur manufacturing facility in June 2025 to build more capacity and capabilities, including high potent oncology, hormones, and steroids, with room for expansion.
- Pithampur is on track for operationalization and validation completion by mid-2026 and expected commercialization by Q1 CY 2027.
- Additional capex of around INR 70 crores was made alongside the Pithampur acquisition.
- The company holds a cash reserve of INR 334 crores, providing "dry powder" for inorganic growth aspirations.
- Evaluations and tactical measures regarding own manufacturing versus outsourcing to optimize margins are ongoing.
2 more points from Rubicon Research's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rubicon Research said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Rubicon Research said on order book & pipeline — free account, 30 seconds.
Rubicon Research — Quarterly revenue & net profit
Rubicon Research Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 476 | 313 | +52.1% | 412 | +15.5% |
| Operating profit (EBITDA) | 108 | 70 | +54.3% | 94 | +14.9% |
| Operating margin | 23% | 22% | +1 pp | 23% | 0 pp |
| Profit before tax | 91 | 53 | +71.7% | 72 | +26.4% |
| Net profit (PAT) | 73 | 38 | +92.1% | 54 | +35.2% |
| EPS (₹) | 4.42 | 2.50 | +76.8% | 3.49 | +26.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹576 Cr, net profit ₹90 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rubicon Research's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rubicon Research and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rubicon Research Q3 FY26 results?
The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products.
What is Rubicon Research share price analysis?
Rubicon Research currently shows a neutral. The stock trades at a P/E of 99.0 with a market cap of ₹28,549 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rubicon Research planning capital expenditure?
The company acquired the Pithampur manufacturing facility in June 2025 to build more capacity and capabilities, including high potent oncology, hormones, and steroids, with room for expansion.
Keep Rubicon Research on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
